PMID- 16083703
OWN - NLM
STAT- MEDLINE
DCOM- 20050907
LR  - 20151119
IS  - 0016-5085 (Print)
IS  - 0016-5085 (Linking)
VI  - 129
IP  - 2
DP  - 2005 Aug
TI  - Insulin-like growth factor-I and insulin are associated with the presence and 
      advancement of adenomatous polyps.
PG  - 464-75
AB  - BACKGROUND & AIMS: Insulin and insulin-like growth factor-I (IGF-I) affect 
      proliferation, differentiation, and apoptosis and are potential risk factors for 
      colorectal cancer (CRC). Visceral obesity, possibly via hyperinsulinemia, has 
      also been linked to CRC risk. We evaluated the relationship of insulin, IGF-I, 
      insulin-like growth factor binding protein (IGFBP) 3, and visceral adipose tissue 
      (VAT) in subjects with adenomatous polyps, the precursor lesion of colorectal 
      cancer. METHODS: Participants were asymptomatic subjects who underwent screening 
      flexible sigmoidoscopy (FSG) within the Prostate, Lung, Colorectal, and Ovarian 
      (PLCO) Cancer Screening Trial. Subjects underwent single-slice, computerized 
      tomography scanning to measure VAT and serum fasting insulin, IGF-I, and IGFBP-3 
      measurements. RESULTS: Four hundred fifty-eight subjects were enrolled, of which 
      202 subjects had an adenoma, 70 of which were an advanced adenoma. IGF-I (P = 
      .02), IGF-I/IGFBP-3 ratio (P = .003), and insulin (P = .02) were significantly 
      increased in subjects with adenomas compared with controls. In an unadjusted 
      logistic regression analysis using sex-specific quartile cut points, subjects in 
      quartile 4 in comparison with quartile 1 of IGF-I (odds ratio [OR] = 1.7; [95% 
      CI: 1.0-2.9], Ptrend = .03), IGF-I/IGFBP-3 ratio (OR = 1.9 [95% CI: 1.1-3.3], 
      Ptrend = .01), and insulin (OR = 2.1 [95% CI: 1.2-3.6], Ptrend = .04) were at 
      increased risk of adenoma. When limiting the case group to advanced adenomas, the 
      effect was more pronounced: IGF-I (OR = 2.8 [95% CI: 1.3-6.2], Ptrend = .006), 
      IGF-I/IGFBP-3 ratio (OR = 2.3, [95% CI: 1.0-5.2], Ptrend = .04), and insulin (OR 
      = 2.3 [95% CI: 1.1-4.9], Ptrend = .14). Visceral adipose tissue was not 
      associated with adenoma risk. CONCLUSIONS: Levels of IGF-I, ratio of 
      IGF-I/IGFBP-3, and insulin are associated with adenomas and even more so with 
      advanced adenomas. These data support the hypothesis that insulin and IGF-I may 
      contribute to the development and advancement of adenomatous polyps.
FAU - Schoen, Robert E
AU  - Schoen RE
AD  - Department of Medicine, University of Pittsburgh, Pennsylvania 15213, USA. 
      rschoen@pitt.edu
FAU - Weissfeld, Joel L
AU  - Weissfeld JL
FAU - Kuller, Lewis H
AU  - Kuller LH
FAU - Thaete, F Leland
AU  - Thaete FL
FAU - Evans, Rhobert W
AU  - Evans RW
FAU - Hayes, Richard B
AU  - Hayes RB
FAU - Rosen, Clifford J
AU  - Rosen CJ
LA  - eng
GR  - K07-CA72561/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Insulin)
RN  - 0 (Insulin-Like Growth Factor Binding Protein 1)
RN  - 0 (Insulin-Like Growth Factor Binding Protein 3)
SB  - IM
MH  - Adenomatous Polyps/blood/epidemiology/*pathology
MH  - Adipose Tissue/metabolism
MH  - Age Distribution
MH  - Aged
MH  - Biomarkers, Tumor/blood
MH  - Biopsy, Needle
MH  - Cohort Studies
MH  - Colonoscopy
MH  - Colorectal Neoplasms/blood/epidemiology/*pathology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Insulin/analysis/*blood
MH  - Insulin-Like Growth Factor Binding Protein 1/analysis/*blood
MH  - Insulin-Like Growth Factor Binding Protein 3/analysis/*blood
MH  - Logistic Models
MH  - Male
MH  - Mass Screening
MH  - Middle Aged
MH  - Neoplasm Invasiveness/*pathology
MH  - Neoplasm Staging
MH  - Prevalence
MH  - Probability
MH  - Prognosis
MH  - Risk Assessment
MH  - Sensitivity and Specificity
MH  - Sex Distribution
MH  - Survival Analysis
EDAT- 2005/08/09 09:00
MHDA- 2005/09/08 09:00
CRDT- 2005/08/09 09:00
PHST- 2005/02/02 00:00 [received]
PHST- 2005/05/11 00:00 [accepted]
PHST- 2005/08/09 09:00 [pubmed]
PHST- 2005/09/08 09:00 [medline]
PHST- 2005/08/09 09:00 [entrez]
AID - S0016-5085(05)01076-0 [pii]
AID - 10.1016/j.gastro.2005.05.051 [doi]
PST - ppublish
SO  - Gastroenterology. 2005 Aug;129(2):464-75. doi: 10.1016/j.gastro.2005.05.051.